The prolongation of QTc-interval by thioridazine [6]

Australian and New Zealand Journal of Psychiatry

Volumn 35, Issue 6, 2001, Pages 857-858

  Sachdev, P ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADALZINE; CHLORPROMAZINE; DROPERIDOL; HALOPERIDOL; NEUROLEPTIC AGENT; PSYCHOTROPIC AGENT; THIORIDAZINE; TRICYCLIC ANTIDEPRESSANT AGENT;

CONTROLLED STUDY; DRUG INDICATION; DRUG METABOLISM; HEART ARRHYTHMIA; HUMAN; LETTER; LONG QT SYNDROME; MEDICAL DECISION MAKING; PRESCRIPTION; SCHIZOPHRENIA; SUDDEN DEATH; TREATMENT FAILURE;

EID: 0035679558     PISSN: 00048674     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1614.2001.0971g.x     Document Type: Letter

References (12)

1. QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients
2. Torsade de pointes: A mechanism for sudden death associated with neuroleptic drug therapy?
3. The association between antipsychotic drugs and sudden death
4. Sudden unexplained death in psychiatric in-patients
5. The effect of thioridazine hydrochloride and chlorpromazine on the electrocardiogram
6. Transient cardiac pacing is insufficiently used to treat arrhythmia associated with thioridazine
7. Survey of sudden death associated with the use of antipsychotic or antidepressant drugs: 49 cases in Finland
8. The antipsychotic agent sertindole is a high affinity antagonist of the human cardiac potassium channel HERG
9. The heart of psychotropic drug therapy
10. The heart of psychotropic drug therapy
11. Psychotropic drugs, HERG, and the heart
12. Risk of torsades de pointes with non-cardiac drugs: Doctors need to be aware that many drugs can cause QT prolongation